Shiseido: The Profit Turn Is Real; the Sales Turn Is Still a Promise
Shiseido: The Profit Turn Is Real; the Sales Turn Is Still a Promise
Shiseido’s 10 November update is a classic turnaround report: the P&L has improved faster than the top line, and management is asking investors to believe that the operating model—not a new strategy—will close the gap. Q3 year-to-date net sales were JPY741.1bn, up 1% year on year; core operating profit was JPY67.5bn, up JPY37.4bn; and profit attributable to owners of the parent was JPY44.4bn, an JPY88.4bn swing. The CFO framed the sales arc as a recovery: “After a 3% decline in Q1, we recorded a 2% growth in Q2 and 3% in Q3, bringing our year-to-date growth to 1%, a shift into positive territory.” — Ayako Hirofuji, CFO · 2026-11-10 That is true, but the absolute level is still thin. The CEO was blunter:
That tension is the story.While our progress of profit generation has exceeded expectation, net sales growth is not satisfactory. We need to heighten the growth speed furthermore.
The P&L is fixed. The top line is not.
The profit improvement is not cosmetic. Cost management was the company’s top-ranked theme this quarter, and the CFO attributed the core profit gain to structural reform benefits, global cost management, and better investment efficiency. Full-year guidance now calls for net sales of JPY1,025bn, core operating profit of JPY87bn and a core operating profit margin of 8.5%, up from 7%, with net profit of JPY62bn. But the raise is partly a currency translation story: “while we lowered our like-for-like growth rate projection based on recent trends, the overall forecast has been revised upward, partly due to the impact of weaker yen on the currency translation.” — Ayako Hirofuji, CFO · 2026-11-10 Management also flagged that asset-sale gains and structural-reform charges should net to zero in non-recurring items, so the headline raise is not a clean organic beat. The contrast with prior calls is sharp. In November 2024, an analyst pressed management on SG&A and the profitability gap with global peers; Fujiwara said the company needed to reach their level. Two years later, 8.5% core OPM is progress, but it is still below the 10%-plus 2030 target and not yet evidence of a peer-beating model. A year ago, the CFO framed the sales ambition as market-plus: “if the market growth is 3%, then we will achieve 5%” — Ayako Hirofuji, CFO · 2025-11-18. Today, like-for-like growth has been cut, so the aspiration is ahead of the reported trajectory.
What is genuinely new: the second winning model
The freshest company-specific language is the winning model—specifically a “second winning model” that uses Shiseido’s accumulated R&D assets to shorten development cycles. The CEO said the company is consolidating basic research into roughly 20 defined domains and shifting to a quantitative, ROI-tracked innovation model. The commercial hook is speed: “By leveraging existing assets, we can cut development time to half the usual period” — Kentaro Fujiwara, President and CEO · 2026-11-10. New products under this model are slated to launch from 2027. This is not a strategic U-turn; the CEO explicitly said “A drastic strategic review is not necessary, but rather the operation to execute the strategy has to be changed.” — Kentaro Fujiwara, President and CEO · 2026-11-10 The accompanying changes—a four-quadrant brand review through an Investment and Divestment Committee, and a 2026 reporting-line shift giving global brand heads more authority over regions—are real operating changes. But they are also a tacit admission that the prior midterm plan did not produce enough top-line traction. The company is not short of strategy; it is short of repeatable execution. That makes 2027 the proof year, not Q4 2026.
Brands and geographies: Max Mara works; Drunk Elephant still does not
The regional mix explains why the profit beat and the sales miss coexist. Japan remained resilient, but the headline consumer purchase number hides a split: “Inbound is -10%, and local is low single digits positive.” — Ayako Hirofuji, CFO · 2026-11-10 China is the bigger puzzle. Management said the prestige market is still growing, but Shiseido’s consumer purchases fell, with Peau Beauté and SHISEIDO weak in Q3 and ANESSA still being reined in. The CFO was candid about the portfolio gap: “fragrance has been keeping high growth. On the other hand, skincare is stagnating, but makeup is doing well too. Portfolio-wise, we have not had a very strong presence in fragrance in China.” — Ayako Hirofuji, CFO · 2026-11-10 Travel retail is improving, and Hainan sell-out was a bright spot—“Consumer purchase or sell-out was very solid. Double-digit growth was recorded in the second quarter, but the third quarter as well, we continue to have a very solid sell-out.” — Kentaro Fujiwara, President and CEO · 2026-11-10—but mainland China travel retail is recovering more slowly than hoped, and management is still managing sell-in against sell-out.
In EMEA, fragrance is the engine. Max Mara had a solid launch in Italy and Germany, and the CEO said Q4 has a richer launch pipeline. But EMEA profit was lower year on year because of first-half marketing and upfront Max Mara investment. The Middle East situation came up in Q&A; management said it has not seen a demand shift and the region is not large enough to move consolidated performance. Americas is the sore spot. Sales turned positive and core operating profit reached JPY5.6bn, helped by Amazon and earlier holiday shipments, but e-commerce deteriorated and Drunk Elephant was the explicit detractor. This is not a new problem. A year ago, management already warned: “in Americas, Drunk Elephant recovery compared to the original assumption expectation, we believe that there will be a delay in recovery, and the performance will remain sluggish.” — Wakako Sato, Analyst · 2025-08-07 Hearing the same brand called out again is a credibility test for the Americas turnaround.
Why it matters
Shiseido is a roughly $10.6bn-market-cap consumer-defensive name, and this report is a “show-me” story rather than a clean re-rating catalyst. The company has done the hard cost work—cumulative cost reduction of JPY72bn under the Action Plan—and that has bought it time. But the quality of the beat depends on items that may not repeat: favorable FX, a tariff refund, and earlier-than-planned asset sales. The global tape has been full of tariff-refund language this year, so Shiseido’s mention is a shared tailwind, not a company-specific edge. Meanwhile, the company-specific issue is consumer purchase momentum: Japan inbound is negative, mainland China is mixed, and the U.S. e-commerce trend weakened in Q3.
The bull case is that 8.5% core OPM is a new base, not a peak, and that the second winning model plus tighter brand capital allocation can lift organic growth into the 2-5% 2030 CAGR. The bear case is that the market has heard “cost discipline” and “brand portfolio review” before, while Drunk Elephant and China prestige remain unresolved. The next catalyst is not the Q4 print alone; it is whether 2027 launches and the new operating cadence produce visible sell-out acceleration. Until then, Shiseido has fixed its profit engine before it has fixed its growth engine—an improvement, but not yet a transformation.